Two recent studies have found that signaling from other ERBB family members is necessary for survival and proliferation in KRAS-driven tumors, and that afatinib and neratinib produce an antitumor response.
Preparing patients for treatment toxicity is important for ensuring that mild or moderate reactions do not undermine adherence.
Cancer Therapy Advisor interviewed Dr Li about her research into the relationship between periodontal disease and gastric cancer.
Although cytogenetic abnormalities that arise during the course of CML are prevalent in later stages of the disease and are associated with a poorer prognosis, as many as 10% to 12% of patients exhibit ACAs at diagnosis.
CONTINUUM suggests that maintenance therapy with lenalidomide is an effective way for prolonging progression-free survival without affecting potential subsequent lines of therapy.
The lesser toxicity of the 20 mg/m2 dose compared with the 25 mg/m2 dose may benefit frail patients in particular, or those with poor functional status.
Several presentations demonstrated that abemaciclib provides clinical benefit for women with HR+/HER2-negative breast cancer who progress on or are resistant to endocrine therapy.
Cancer Therapy Advisor interviewed Keith Flaherty, MD, about recent findings regarding targeted therapies for melanoma.
According to a study across all 32 cancer types, data suggest that 66% of mutations leading to cancer are the result of random events.
Patients with relapsed or refractory MCL treated with ibrutinib had longer PFS with less toxicity than patients treated with temsirolimus in a phase 3 trial.
